Nuvectis Pharma (NVCT) Gains from Investment Securities (2021 - 2026)

Nuvectis Pharma has disclosed Gains from Investment Securities across 6 years of filings, most recently posting $847904.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $847904.0, changed 0.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $847904.0 (changed 0.45% YoY), and the FY2025 annual result was $348281.0, changed 0.0% from the prior year.
• Gains from Investment Securities came in at $847904.0 for Q1 2026 at Nuvectis Pharma, up from $348281.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.1 million in Q3 2025 to a low of $226590.0 in Q1 2022.
• The 5-year median for Gains from Investment Securities is $348281.0 (2023), against an average of $480393.4.
• Across the five-year window, Gains from Investment Securities surged 554.88% in 2022 and plunged 40.01% in 2025, its largest moves.
• Nuvectis Pharma's Gains from Investment Securities stood at $311590.0 in 2022, then gained by 11.78% to $348281.0 in 2023, then changed by 0.0% to $348281.0 in 2024, then changed by 0.0% to $348281.0 in 2025, then surged by 143.45% to $847904.0 in 2026.
• The last three Gains from Investment Securities figures came in at $847904.0 (Q1 2026), $348281.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.